(Q44536841)

English

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

scientific article published in November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Solbritt Rantapää Dahlqvist

13

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ronald van Vollenhoven

2

object named as

Ronald F van Vollenhoven

0 references

10

object named as

Pierre Geborek

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

14

object named as

Tore Saxne

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

6

object named as

Eva Baecklund

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Christina Dackhammar

7

object named as

Christina Dackhammar

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

8

object named as

Nils Feltelius

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Staffan Lindblad

12

object named as

Staffan Lindblad

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1

object named as

Johan Askling

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

9

object named as

Lars Cöster

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Fredrik Granath

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Pauline Raaschou

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C Michael Fored

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lennart T Jacobsson

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3180-3189

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

TNF-alpha in promotion and progression of cancer

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

NF-kappaB: tumor promoter or suppressor?

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Swedish registers to examine drug safety and clinical issues in RA.

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Rheumatoid arthritis and cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978.

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FART.24941

21 January 2018

Identifiers

10.1002/ART.24941

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44536841&oldid=1859045067"